Back to Search Start Over

SARS CoV-2 Genomic Characteristics and Clinical Impact of SARS-CoV-2 Viral Diversity in Critically Ill COVID-19 Patients: A Prospective Multicenter Cohort Study

Authors :
Slim Fourati
Etienne Audureau
Romain Arrestier
Stéphane Marot
Claire Dubois
Guillaume Voiriot
Charles-Edouard Luyt
Tomas Urbina
Julien Mayaux
Anne-Marie Roque-Afonso
Tài Pham
Luce Landraud
Benoit Visseaux
Damien Roux
Raphael Bellaiche
Anne-Sophie L’honneur
Zakaria Ait Hamou
Ségolène Brichler
Stéphane Gaudry
Maud Salmona
Raphaël Clere-Jehl
Elie Azoulay
Laurence Morand-Joubert
Anne-Geneviève Marcelin
Marie-Laure Chaix
Diane Descamps
Armand Mekontso Dessap
Christophe Rodriguez
Jean-Michel Pawlotsky
Nicolas de Prost
Hôpital Henri Mondor
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
IMRB - VHC/'Viruses-Hepatology-Cancers' [Créteil] (U955 Inserm - UPEC)
Institut Mondor de Recherche Biomédicale (IMRB)
Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
IMRB - CEPIA/'Clinical Epidemiology And Ageing : Geriatrics, Primary Care and Public Health' [Créteil] (U955 Inserm - UPEC)
Groupe de recherche clinique CARMAS (Cardiovascular and Respiratory Manifestations of Acute lung injury and Sepsis) (CARMAS)
CHU Tenon [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Henri Mondor
Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)
CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
CHU Saint-Antoine [AP-HP]
Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Hôpital Paul Brousse
Centre de recherche en épidémiologie et santé des populations (CESP)
Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay
Hôpital Bicêtre
Hôpital Louis Mourier - AP-HP [Colombes]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137))
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord
Département Médico-Universitaire Épidémiologie et biostatistique, Santé publique, Pharmacie, Pharmacologie, Recherche, Information médicale, Thérapeutique et médicaments) (DMU Esprit)
CHU Charles Foix [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Tenon [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Trousseau [APHP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Rothschild [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Saint-Antoine [AP-HP]
Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151))
Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)
Hôpital Cochin [AP-HP]
Hôpital Avicenne [AP-HP]
Hopital Saint-Louis [AP-HP] (AP-HP)
Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976))
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)
Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
HAL UVSQ, Équipe
Source :
Viruses; Volume 14; Issue 7; Pages: 1529, Viruses, Viruses, MDPI, 2022, 14 (7), pp.1529. ⟨10.3390/v14071529⟩, Viruses, 2022, 14 (7), pp.1529. ⟨10.3390/v14071529⟩
Publication Year :
2022
Publisher :
Research Square Platform LLC, 2022.

Abstract

Background: SARS-CoV-2 variant of concern (VOC) α spread worldwide, including in France, at the beginning of 2021. This variant was suggested to be associated with a higher risk of mortality than other variants. Little information is available in the subset of patients with severe disease admitted in the intensive care unit (ICU). We aimed to characterize the genetic diversity of SARS-CoV-2 variants isolated from patients with severe COVID-19 in order to unravel the relationships between specific viral mutations/mutational patterns and clinical outcomes.Methods: Prospective multicentre observational cohort study. Patients aged ≥18 years admitted in 11 ICUs from Great Paris area hospitals between October 1, 2020, and May 30, 2021 (before the introduction of VOC δ (B.617.2) in France) for acute respiratory failure (SpO2≤90% and need for supplemental oxygen or ventilator support) were included. SARS-CoV-2 infection, determined by RT-PCR testing. The primary clinical endpoint was day-28 mortality. Full-length SARS-CoV-2 genomes were sequenced by means of next-generation sequencing (Illumina COVIDSeq).Results: 413 patients were included, 183 (44.3%) had been infected with pre-existing variants, 197 (47.7%) with variant α (B.1.1.7), and 33 (8.0%) with other variants. Patients infected with pre-existing variants were significantly older (64.9±11.9 vs 60.5±11.8 years; p=0.0005); they had significantly more frequent COPD (11.5% (n=21/183) vs 4.1% (n=8/197); p=0.009), and higher SOFA score (4 [3-8] vs 3 [2-4]; 0.0002). Day-28 mortality was not different between patients infected with pre-existing, α (B.1.1.7) or other variants (31.1% (n=57/183) vs 26.2% (n=51/197) vs 30.3% (n=10/33), respectively; p=0.550). There was no association between day-28 mortality with a specific variant or the presence of specific mutations in SARS CoV-2 genome, including 17 mutations selected in the spike protein and all 1017 non-synonymous mutations detected throughout the entire viral genome.Conclusions: At ICU admission, patients infected with pre-existing variants had a different clinical presentation from those infected with variant α (B.1.1.7) and other variants later in the course of the pandemic, but mortality did not differ between these groups. There was no association between a specific variant or SARS CoV-2 genome mutational pattern and day-28 mortality.

Details

ISSN :
19994915
Database :
OpenAIRE
Journal :
Viruses; Volume 14; Issue 7; Pages: 1529, Viruses, Viruses, MDPI, 2022, 14 (7), pp.1529. ⟨10.3390/v14071529⟩, Viruses, 2022, 14 (7), pp.1529. ⟨10.3390/v14071529⟩
Accession number :
edsair.doi.dedup.....9ad3f77c7fdd4f96350cee2b62a9745f